[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
71 patients (42 males and 29 females at the age of 45-76 years) with primary hyperlipoproteinaemia were treated with clofibrin acid and derivatives of nicotinic acid during 3 years. Gas-chromatographic analyses of the composition of fatty acids of their serum cholesterol ester and triglyceride fractions showed an increase of linoleic, linolenic, arachidonic, eicosapentaenic acid as well as a decrease of palmitinic, palmitoleinic, stearic, oleic and eicosatrienic acid under treatment. The changes were more efficient than under monotherapy. Selective competitive inhibition of unesterified fatty acid, blocking of lipolysis, influence on the hepatogenic metabolism of fatty acids and on the LCAT as well as better utilization of the alimentary repeatedly unsaturated fatty acids were discussed as possible mechanism. The increase of the polyunsaturated fatty acids with their interrelations to the prostaglandin metabolism must be seen in the sense of a vasoprotective effect.
D000368:Aged; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy; D006951:Hyperlipoproteinemias / Q000188:drug therapy* / Q000378:metabolism; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage*
D005227:Fatty Acids; D009539:Nicotinic Acids; D002995:Clofibric Acid; D002994:Clofibrate
Wirkungen der Kombinationsbehandlung von Klofibrinsäure und Nikotinsäurederivaten auf den Fettsäurestoffwechsel bei Hyperlipoproteinämie.